NO20061541L - Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister - Google Patents

Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister

Info

Publication number
NO20061541L
NO20061541L NO20061541A NO20061541A NO20061541L NO 20061541 L NO20061541 L NO 20061541L NO 20061541 A NO20061541 A NO 20061541A NO 20061541 A NO20061541 A NO 20061541A NO 20061541 L NO20061541 L NO 20061541L
Authority
NO
Norway
Prior art keywords
gastroparesis
treatment
baclofen
methods
formulations
Prior art date
Application number
NO20061541A
Other languages
English (en)
Norwegian (no)
Inventor
John G Devane
Jackie Butler
Original Assignee
Agi Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agi Therapeutics Ltd filed Critical Agi Therapeutics Ltd
Publication of NO20061541L publication Critical patent/NO20061541L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061541A 2003-09-12 2006-04-05 Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister NO20061541L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50224203P 2003-09-12 2003-09-12
US55394004P 2004-03-18 2004-03-18
PCT/IB2004/003299 WO2005025559A1 (fr) 2003-09-12 2004-09-10 Traitement de gastroparesie et de dyspepsie non ulcereuse avec des agonistes de gabab

Publications (1)

Publication Number Publication Date
NO20061541L true NO20061541L (no) 2006-04-05

Family

ID=34316518

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061541A NO20061541L (no) 2003-09-12 2006-04-05 Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister

Country Status (9)

Country Link
US (2) US20050090554A1 (fr)
EP (1) EP1675581A1 (fr)
JP (1) JP2007505099A (fr)
AU (1) AU2004271805A1 (fr)
CA (1) CA2537343A1 (fr)
IL (1) IL173930A0 (fr)
MX (1) MXPA06002572A (fr)
NO (1) NO20061541L (fr)
WO (1) WO2005025559A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7824697B2 (en) 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
AU2007201808B8 (en) * 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity
WO2008011016A2 (fr) * 2006-07-18 2008-01-24 Dynogen Pharmaceuticals, Inc. Méthodes de traitement du reflux gastrooesophagien
EP2058008B1 (fr) * 2006-08-11 2013-08-21 National University Corporation Nagoya University Agent anti-obésité et son utilisation
EP2578216A1 (fr) * 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Procédés de traitement du syndrome de l'X fragile
US20150258279A1 (en) 2008-03-18 2015-09-17 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms and related delivery system
US8969414B2 (en) * 2009-02-06 2015-03-03 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
CA2745741A1 (fr) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Systeme de d'administration de medicament a retention gastrique pour le zaleplon
JPWO2010104175A1 (ja) * 2009-03-13 2012-09-13 味の素株式会社 経口用組成物
WO2010133961A1 (fr) * 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Compositions à libération prolongée à base de cyclobenzaprine
CA2786777A1 (fr) * 2010-01-07 2011-07-14 Akron Molecules Gmbh Petites molecules pour traiter l'obesite
KR101351181B1 (ko) 2010-05-11 2014-01-14 가천대학교 산학협력단 단핵식세포계 세포 내에서 ａｇｅ-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
EP2705842A1 (fr) * 2012-09-05 2014-03-12 Pharnext Approches thérapeutiques pour le traitement de la maladie de Parkinson
DK2688648T3 (en) 2011-03-23 2016-03-14 Raqualia Pharma Inc 5-HT 4 receptor agonist as a prokinetic agent
FR2991879B1 (fr) * 2012-06-14 2014-11-21 Ethypharm Sa Formulation pharmaceutique orale de molecules bcs de classe iii
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
JP6754033B2 (ja) 2014-05-16 2020-09-09 ラクオリア創薬株式会社 胃不全麻痺のための５−ｈｔ４受容体作動薬
WO2016132218A1 (fr) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Méthode d'administration de r-baclofène dans une forme pharmaceutique à libération prolongée
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10987311B2 (en) * 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) * 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
EP4056172A1 (fr) * 2018-06-18 2022-09-14 Amneal Complex Products Research LLC Compositions à libération prolongée comprenant de la pyridostigmine
CN113164423A (zh) * 2018-10-04 2021-07-23 美德阿利克斯株式会社 用非水溶剂稳定化的制剂
WO2023055457A1 (fr) * 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Formulations en granules contenant du baclofène et réduction des variations de l'exposition du patient aux métabolites
US11491125B1 (en) 2021-09-29 2022-11-08 Amneal Pharmaceuticals Llc Baclofen formulations and methods of minimizing patient exposure to metabolite variations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308430D0 (en) * 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
CA2240937C (fr) * 1995-12-20 2004-06-01 Farmarc Nederland B.V. Procede de resolution optique de 3-(p-chlorophenyl)-glutaramide
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
WO2003026631A1 (fr) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
CA2483687A1 (fr) * 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Distribution de medicament a base d'amines par voie d'inhalation
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법

Also Published As

Publication number Publication date
MXPA06002572A (es) 2006-06-05
US20090246233A1 (en) 2009-10-01
IL173930A0 (en) 2006-07-05
AU2004271805A1 (en) 2005-03-24
JP2007505099A (ja) 2007-03-08
CA2537343A1 (fr) 2005-03-24
WO2005025559A1 (fr) 2005-03-24
EP1675581A1 (fr) 2006-07-05
US20050090554A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
NO20061541L (no) Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister
NO20054546L (no) Kinazoliner anvendelige som modulatorer av ionekanaler
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
HK1125039A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20054848L (no) Substituerte p-diaminobenzenderivater
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
DE60306546D1 (de) Entzündungshemmende 3-arylthio-3-thiazolylalkylamine
ATE344262T1 (de) 2-heteroarylcarbonsäureamide
SE0004101D0 (sv) New use
HK1106246A1 (en) S-tenatoprazole monohydrated sodium salt and the use thereof in therapy s-
NO20063790L (no) Substituerte azetidin sammensetninger som cyclooxygenase-1-cyclooxygenase-2-inhibitorer, og deres fremstilling og anvendelse som medikamenter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application